Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

43.19 -0.81 (-1.84%)
Streaming Delayed Price Updated: 9:57 AM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 308,634
Open 43.31
Bid (Size) 43.18 (700)
Ask (Size) 43.19 (100)
Prev. Close 44.00
Today's Range 43.05 - 43.45
52wk Range 40.89 - 52.68
Shares Outstanding 1,250,690,553
Dividend Yield 5.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗
Via Chartmill
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool

Performance

YTD
-10.4%
-10.4%
1 Month
-1.4%
-1.4%
3 Month
-8.0%
-8.0%
6 Month
-9.3%
-9.3%
1 Year
-11.0%
-11.0%

More News

Read More
News headline image
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗
Via The Motley Fool
Topics Intellectual Property
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals ↗
Via Chartmill
SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals ↗
Via Chartmill
Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals ↗
Via Chartmill
Sanofi (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals and a 5.26% Payout ↗
Via Chartmill
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 Dirt Cheap Growth Stock to Buy Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool
News headline image
Is This Biotech Stock a Buy After a Groundbreaking Approval? ↗
Via The Motley Fool
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
Via The Motley Fool
News headline image
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10% ↗
Via MarketBeat
News headline image
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗
Via The Motley Fool
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Via MarketMinute
Topics Intellectual Property
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
Via MarketMinute
Topics Economy World Trade
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
Via MarketMinute
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 43.19
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 07/14/26 09:57 AM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 54.02B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 54B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.